Breaking New Ground: Innovations in Alzheimer’s Research
Alzheimer’s disease is currently the sixth leading cause of death in the United States. While recent data indicate nearly six million Americans currently live with the disease, some estimates suggest that number could triple by 2060, causing yearly treatment costs in the hundreds of billions of dollars.
What innovations show the most promise for early detection and treatment for this disease that takes a crushing toll on patients, their loved ones and caregivers? How are researchers and doctors better understanding risk factors and diagnoses? Since Black and Latino Americans and women are more likely to develop Alzheimer’s, how can underserved groups be given equitable access to care, education, and clinical trials? And how can policies prioritize research, awareness, detection and treatment?
Wednesday, March 2, 2022
1:00 PM ET / 10:00 AM PT
- Aisha Adkins, Constituency Organizer, Caring Across Generations
- Rep. Nanette Barragán (D-CA), Member, Energy & Commerce Subcommittee on Health
- Sen. Roy Blunt (R-MO), Chair, Senate Republican Policy Committee; Ranking Member, Appropriations Subcommittee on Labor, HHS, and Education
- Dr. Maria Carrillo, Chief Science Officer, Alzheimer’s Association
- Rep. Markwayne Mullin (R-OK), Co-chair, Congressional Social Determinants of Health Caucus
- Petra Niles, Gerontologist & Senior Manager, African American Services, Alzheimer’s Los Angeles
- Kathryn Schubert, President & CEO, Society for Women’s Health Research
- Rachel Sher, Life Sciences & FDA Partner, Manatt, Phelps & Phillips; Former Senior Policy Analyst, FDA
- Nora Super, Executive Director, Center for the Future of Aging, Milken Institute
- Rep. Paul Tonko (D-NY), Member, Bipartisan Congressional Task Force on Alzheimer’s disease
- Brent Vaughan, CEO, Cognito Therapeutics
- George Vradenburg, Chair & Co-founder, UsAgainstAlzheimer’s
- Dr. Elias Zerhouni, Former Director, NIH
- Anne White, SVP and President of Lilly Neuroscience, Eli Lilly & Company
- Steve Clemons, Editor-at-Large, The Hill
Join the conversation! Tweet us: @TheHillEvents using #TheHillAlz
With more than 30 years of dedication to finding solutions for Alzheimer’s, Lilly is proud of our progress to advance the science for this devastating disease. Lilly is committed to pursuing the best possible outcomes for the Alzheimer’s disease community, which is why we support policies that enable patient access to advanced diagnostics for Alzheimer’s and enable improved training of health care providers to diagnose Alzheimer’s. We remain hopeful for patients and their families.